Adaptive Biotechnologies Valuation
| ADPT Stock | USD 15.70 0.09 0.57% |
At this time, the firm appears to be undervalued. Adaptive Biotechnologies shows a prevailing Real Value of $17.33 per share. The current price of the firm is $15.7. Our model approximates the value of Adaptive Biotechnologies from analyzing the firm fundamentals such as return on equity of -0.28, and Profit Margin of (0.21) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Adaptive Biotechnologies' valuation include:
Price Book 11.2738 | Enterprise Value | Enterprise Value Ebitda (1.00) | Price Sales 8.9055 | Enterprise Value Revenue 8.3718 |
Undervalued
Today
Please note that Adaptive Biotechnologies' price fluctuation is somewhat reliable at this time. Calculation of the real value of Adaptive Biotechnologies is based on 3 months time horizon. Increasing Adaptive Biotechnologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Adaptive Biotechnologies' intrinsic value may or may not be the same as its current market price of 15.70, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.7 | Real 17.33 | Target 20.86 | Hype 15.73 |
The intrinsic value of Adaptive Biotechnologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Adaptive Biotechnologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Adaptive Biotechnologies Corp helps investors to forecast how Adaptive stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Adaptive Biotechnologies more accurately as focusing exclusively on Adaptive Biotechnologies' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Adaptive Biotechnologies' intrinsic value based on its ongoing forecasts of Adaptive Biotechnologies' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Adaptive Biotechnologies' closest peers.
Adaptive Biotechnologies Cash |
|
Adaptive Biotechnologies Total Value Analysis
Adaptive Biotechnologies Corp is presently projected to have valuation of 2.32 B with market capitalization of 2.47 B, debt of 280.58 M, and cash on hands of 383.74 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Adaptive Biotechnologies fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.32 B | 2.47 B | 280.58 M | 383.74 M |
Adaptive Biotechnologies Investor Information
About 100.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.39. Adaptive Biotechnologies had not issued any dividends in recent years. Based on the key indicators related to Adaptive Biotechnologies' liquidity, profitability, solvency, and operating efficiency, Adaptive Biotechnologies Corp is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Adaptive Biotechnologies Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Adaptive Biotechnologies has an asset utilization ratio of 54.02 percent. This implies that the Company is making $0.54 for each dollar of assets. An increasing asset utilization means that Adaptive Biotechnologies Corp is more efficient with each dollar of assets it utilizes for everyday operations.Adaptive Biotechnologies Profitability Analysis
Based on Adaptive Biotechnologies' profitability indicators, Adaptive Biotechnologies Corp may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Adaptive Biotechnologies' ability to earn profits and add value for shareholders.Net Loss | First Reported 2018-03-31 | Previous Quarter 9.5 M | Current Value -13.6 M | Quarterly Volatility 18.9 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.54 | 0.7424 |
|
|
For Adaptive Biotechnologies profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Adaptive Biotechnologies to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Adaptive Biotechnologies utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Adaptive Biotechnologies's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Adaptive Biotechnologies over time as well as its relative position and ranking within its peers.
Adaptive Biotechnologies Earnings per Share Projection vs Actual
The next projected EPS of Adaptive Biotechnologies is estimated to be -0.1343 with future projections ranging from a low of -0.15 to a high of -0.12. Adaptive Biotechnologies' most recent 12-month trailing earnings per share (EPS TTM) is at -0.39. Please be aware that the consensus of earnings estimates for Adaptive Biotechnologies Corp is based on EPS before non-recurring items and includes expenses related to employee stock options.Adaptive Biotechnologies Earnings Estimation Breakdown
The calculation of Adaptive Biotechnologies' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Adaptive Biotechnologies is estimated to be -0.1343 with the future projection ranging from a low of -0.15 to a high of -0.12. Please be aware that this consensus of annual earnings estimates for Adaptive Biotechnologies Corp is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.15 Lowest | Expected EPS | -0.12 Highest |
Adaptive Biotechnologies Earnings Projection Consensus
Suppose the current estimates of Adaptive Biotechnologies' value are higher than the current market price of the Adaptive Biotechnologies stock. In this case, investors may conclude that Adaptive Biotechnologies is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Adaptive Biotechnologies' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 8 | 58.79% | 0.0 | -0.1343 | -0.39 |
Adaptive Biotechnologies Ownership Allocation
Adaptive Biotechnologies holds a total of 153.78 Million outstanding shares. The majority of Adaptive Biotechnologies Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Adaptive Biotechnologies to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Adaptive Biotechnologies. Please pay attention to any change in the institutional holdings of Adaptive Biotechnologies Corp as this could imply that something significant has changed or is about to change at the company. Also note that nearly two million seven hundred fifty-two thousand six hundred fifty-two invesors are currently shorting Adaptive Biotechnologies expressing very little confidence in its future performance.Adaptive Biotechnologies Profitability Analysis
The company reported the previous year's revenue of 276.98 M. Net Loss for the year was (159.59 M) with profit before overhead, payroll, taxes, and interest of 111.85 M.About Adaptive Biotechnologies Valuation
The stock valuation mechanism determines Adaptive Biotechnologies' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Adaptive Biotechnologies based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Adaptive Biotechnologies. We calculate exposure to Adaptive Biotechnologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Adaptive Biotechnologies's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 205.6 M | 215.9 M | |
| Pretax Profit Margin | (0.21) | (0.23) | |
| Operating Profit Margin | (0.21) | (0.22) | |
| Net Loss | (0.21) | (0.23) | |
| Gross Profit Margin | 0.74 | 0.54 |
Adaptive Biotechnologies Current Valuation Indicators
Adaptive Biotechnologies' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Adaptive Biotechnologies' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Adaptive Biotechnologies, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Adaptive Biotechnologies' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Adaptive Biotechnologies' worth.Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.